{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:49:57Z","timestamp":1776426597943,"version":"3.51.2"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims:<\/jats:title>\n                    <jats:p>Conversion therapy may transform some unresectable hepatocellular carcinomas (uHCCs) into curable ones, but data remained limited comparing subsequent curative-intent treatment options. Therefore, we aimed to compare the efficacy and safety of surgical resection (SR) and microwave ablation (MWA) following conversion for initially uHCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>From June 2008 to October 2022, this multi-center retrospective study included 1035 consecutive patients with treatment-naive BCLC A\/B beyond-Milan uHCC receiving curative-intent SR or MWA after successful conversion from 15 tertiary-care hospitals. For the propensity score-matched cohort, overall survival (OS), recurrence-free survival (RFS), and treatment-related complications were compared; a risk-stratification Conversion-Ablation or REsection (CARE) score was developed for OS and externally compared against major prognostic models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After matching (421 patients in each treatment group), SR was associated with similar RFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.167), less beyond-Milan recurrence (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.003), and longer OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.001) compared with MWA. Developed as \u201c10\u00a0\u00d7\u00a0baseline AFP (&gt;400\u00a0ng\/mL,1;\u00a0\u2264\u00a0400\u00a0ng\/mL,0)-baseline albumin (g\/L)-35\u00a0\u00d7\u00a0objective response to conversion therapy per mRECIST (yes,1;no,0),\u201d CARE outperformed major prognostic models (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -values,\u00a0&lt;0.001 to 0.025) and allowed effective stratification of OS and RFS (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.001). OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.159) and RFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.573) were similar between the two treatment groups for the CARE-identified low-risk patients (\u2264\u221246.6), but SR was associated with longer OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.001) and RFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.001) for the CARE-identified high-risk ones (&gt;\u221246.6). Treatment-related complications were comparable between two groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -values, 0.147 to &gt;0.999).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>For initially BCLC A\/B uHCC beyond the Milan criteria, SR was associated with longer OS and similar RFS compared with MWA after conversion. The CARE score might assist in personalized risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004486","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:01:11Z","timestamp":1765983671000},"page":"7758-7770","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Resection versus microwave ablation following conversion therapy for unresectable hepatocellular carcinoma"],"prefix":"10.1097","volume":"112","author":[{"given":"Hanyu","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxuan","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Interventional Therapy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Interventional therapy, Guangdong Provincial Hospital of Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[{"name":"Department of Radiology, Universit\u00e9 Paris Cit\u00e9, UMR 1149, CRI, Paris & Service de Radiologie, Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"},{"name":"Department of Radiology, Sanya People\u2019s Hospital, Sanya, Hainan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"an","sequence":"additional","affiliation":[{"name":"Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R1-20260417","first-page":"229\u201363","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260417","article-title":"Electronic address eee, European association for the study of the L. EASL clinical practice guidelines on the management of hepatocellular carcinoma","year":"2024","journal-title":"J Hepatol"},{"key":"R3-20260417","doi-asserted-by":"crossref","first-page":"1922\u201365","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"R4-20260417","first-page":"1\u201357","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 Edition)","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"R5-20260417","doi-asserted-by":"crossref","first-page":"1492\u2013501","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"R6-20260417","first-page":"1\u201314","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"R7-20260417","doi-asserted-by":"crossref","first-page":"117\u201327","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"R8-20260417","doi-asserted-by":"crossref","first-page":"169\u201378","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R9-20260417","doi-asserted-by":"crossref","first-page":"707\u201315","DOI":"10.1148\/radiol.2019181991","article-title":"Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes","volume":"293","author":"Shi","year":"2019","journal-title":"Radiology"},{"key":"R10-20260417","doi-asserted-by":"crossref","first-page":"3073\u201383","DOI":"10.1245\/s10434-024-14944-3","article-title":"Outcomes of salvage surgery versus non-salvage surgery for initially unresectable hepatocellular carcinoma after conversion therapy with transcatheter arterial chemoembolization combined with lenvatinib plus Anti-PD-1 antibody: a multicenter retrospective study","volume":"31","author":"Wu","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R11-20260417","doi-asserted-by":"crossref","first-page":"102367","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R12-20260417","doi-asserted-by":"crossref","first-page":"227\u201352","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R13-20260417","doi-asserted-by":"crossref","first-page":"681\u201393","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"R14-20260417","doi-asserted-by":"crossref","first-page":"4657\u201366","DOI":"10.1007\/s00330-022-08537-5","article-title":"Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study","volume":"32","author":"Zheng","year":"2022","journal-title":"Eur Radiol"},{"key":"R15-20260417","doi-asserted-by":"crossref","first-page":"4764\u201373","DOI":"10.1007\/s00330-020-07571-5","article-title":"Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis","volume":"31","author":"An","year":"2021","journal-title":"Eur Radiol"},{"key":"R16-20260417","doi-asserted-by":"crossref","first-page":"66\u201377","DOI":"10.1002\/hep.32323","article-title":"Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC","volume":"76","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"R17-20260417","doi-asserted-by":"crossref","first-page":"1356\u201366","DOI":"10.1097\/JS9.0000000000001398","article-title":"A multicenter case-controlled study on laparoscopic hepatectomy versus microwave ablation as first-line therapy for 3-5 cm hepatocellular carcinoma in patients aged 60 and older","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"R18-20260417","doi-asserted-by":"crossref","first-page":"254\u201362","DOI":"10.1016\/j.surg.2019.05.007","article-title":"Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma \u22645 cm: a propensity score-matched analysis","volume":"166","author":"Ryu","year":"2019","journal-title":"Surgery"},{"key":"R19-20260417","first-page":"1938\u201348","article-title":"Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score-matched study of long-term therapeutic outcomes","volume":"33","author":"Liu","year":"2023","journal-title":"Eur Radiol"},{"key":"R20-20260417","doi-asserted-by":"crossref","first-page":"1602\u201314","DOI":"10.1111\/apt.17263","article-title":"Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per barcelona clinic liver cancer staging: a propensity score matching and inverse probability of treatment weighting analysis","volume":"56","author":"Tong","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20260417","first-page":"100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R22-20260417","doi-asserted-by":"crossref","first-page":"320\u201329","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and Anti-PD-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"key":"R23-20260417","doi-asserted-by":"crossref","first-page":"2910\u201321","DOI":"10.1097\/JS9.0000000000001193","article-title":"Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb\/IIIa stage: a propensity score matching study","volume":"110","author":"Ma","year":"2024","journal-title":"Int J Surg"},{"key":"R24-20260417","first-page":"131\u201336","article-title":"Expert opinion on expanding anti-HBV treatment for chronic hepatitis B","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"R25-20260417","doi-asserted-by":"crossref","first-page":"288\u2013306","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"R26-20260417","first-page":"192\u2013202","article-title":"Machine learning predictive model to guide treatment allocation for recurrent hepatocellular carcinoma after surgery","volume":"158","author":"Famularo","year":"2023","journal-title":"JAMA Surg"},{"key":"R27-20260417","doi-asserted-by":"crossref","first-page":"471\u201378","DOI":"10.1097\/SLA.0000000000006056","article-title":"A prognostic model to predict survival after recurrence among patients with recurrent hepatocellular carcinoma","volume":"279","author":"Moazzam","year":"2024","journal-title":"Ann Surg"},{"key":"R28-20260417","doi-asserted-by":"crossref","first-page":"995\u20131004","DOI":"10.1016\/j.jhep.2024.06.018","article-title":"Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection","volume":"81","author":"Fuster-Anglada","year":"2024","journal-title":"J Hepatol"},{"key":"R30-20260417","first-page":"583\u2013705","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R31-20260417","doi-asserted-by":"crossref","first-page":"893\u2013903","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"China HCC-TACE study group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J Hepatol"},{"key":"R32-20260417","doi-asserted-by":"crossref","first-page":"203\u201315","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"R33-20260417","doi-asserted-by":"crossref","first-page":"564\u201371","DOI":"10.1097\/SLA.0000000000003268","article-title":"Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation","volume":"273","author":"Lee","year":"2021","journal-title":"Ann Surg"},{"key":"R34-20260417","doi-asserted-by":"crossref","first-page":"397\u2013413","DOI":"10.1159\/000505694","article-title":"Deep learning radiomics based on contrast-enhanced ultrasound might optimize curative treatments for very-early or early-stage hepatocellular carcinoma patients","volume":"9","author":"Liu","year":"2020","journal-title":"Liver Cancer"},{"key":"R35-20260417","first-page":"525\u201337","article-title":"LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs radiofrequency ablation","volume":"34","author":"Min","year":"2024","journal-title":"Eur Radiol"},{"key":"R36-20260417","doi-asserted-by":"crossref","first-page":"1339\u201356","DOI":"10.1002\/hep.31766","article-title":"Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N6-Methyladenosine mRNA methylation-dependent mechanism","volume":"74","author":"Su","year":"2021","journal-title":"Hepatology"},{"key":"R37-20260417","doi-asserted-by":"crossref","first-page":"29\u201340","DOI":"10.1016\/j.canlet.2019.05.041","article-title":"Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner","volume":"460","author":"Tan","year":"2019","journal-title":"Cancer Lett"},{"key":"R38-20260417","doi-asserted-by":"crossref","first-page":"554\u201361","DOI":"10.1148\/radiol.2020192797","article-title":"Diagnostic performance of LI-RADS treatment response algorithm for hepatocellular carcinoma: adding ancillary features to MRI compared with enhancement patterns at CT and MRI","volume":"296","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"R39-20260417","doi-asserted-by":"crossref","first-page":"4785\u201393","DOI":"10.1007\/s00330-020-07464-7","article-title":"Diagnostic performance of liver imaging reporting and data system treatment response algorithm: a systematic review and meta-analysis","volume":"31","author":"Youn","year":"2021","journal-title":"Eur Radiol"},{"key":"R40-20260417","first-page":"142\u201357","article-title":"Depth of radiographic response as an independent prognostic factor for patients with initially unresectable hepatocellular carcinoma receiving hepatectomy following targeted therapy plus immunotherapy","volume":"14","author":"Wl-n","year":"2024","journal-title":"Liver Cancer"},{"key":"R41-20260417","doi-asserted-by":"crossref","first-page":"5672\u201384","DOI":"10.1097\/JS9.0000000000001752","article-title":"Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study","volume":"110","author":"Jiang","year":"2024","journal-title":"Int J Surg"},{"key":"R42-20260417","doi-asserted-by":"crossref","first-page":"947\u201356","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"R43-20260417","doi-asserted-by":"crossref","first-page":"342\u201348","DOI":"10.1016\/j.jhep.2020.03.018","article-title":"Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant","volume":"73","author":"Cucchetti","year":"2020","journal-title":"J Hepatol"},{"key":"R44-20260417","doi-asserted-by":"crossref","first-page":"1502\u201312","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"R45-20260417","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1002\/mog2.60","article-title":"Novel insights into HBV-hepatocellular carcinoma at single-cell sequencing","volume":"2","author":"Yin","year":"2023","journal-title":"MedComm-Oncology"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:00:58Z","timestamp":1776423658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004486","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"2025-08-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}